VIDEO: PERSEUS trial results ‘practice-changing’ for newly diagnosed multiple myeloma
Click Here to Manage Email Alerts
Healio spoke with Chakra Chaulagain, MD, about phase 3 PERSEUS trial results presented at ASH 2023.
Findings from the randomized trial showed that among patients with newly diagnosed multiple myeloma, daratumumab (Darzalex, Janssen) combined with bortezomib (Velcade, Millenium/Takeda), lenalidomide (Revlimid, Bristol Myers Squibb) and dexamethasone was more effective than bortezomib, lenalidomide and dexamethasone alone.
“These data are really practice-changing,” Chaulagain, director of the myeloma and amyloidosis program at Cleveland Clinic Florida, told Healio. “We have been using the quadruplet therapy in this patient population for some time, but this is very robust data reaffirming that the quadruplet therapy is the way to go to treat newly diagnosed transplant-eligible multiple myeloma patients moving forward.”
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts